BeyondSpring (BYSI)
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology...
- Open
- 0.7600
- High
- 0.7900
- Low
- 0.7600
- Prev. Close
- 0.7420
- Volume
- 989
- Turnover
- 754.69
- Avg Price
- 0.7631
- Bid/Ask Ratio
- 97.11%
- Amplitude
- 4.04%
- 52wk High
- 2.4400
- Volume Ratio
- 0.57
- Turnover Ratio
- 0.00%
BeyondSpring Analyst Rating
View moreForecast & Rating
Nov 7, 2023Price forecast
$1.2558.23%
Forecast & RatingStrong buy
1analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 9 at 01:18 PM
BeyondSpring posts corporate presentation spotlighting plinabulin immune-modulating cancer therapy pipeline
- PUBT · Jul 6 at 12:09 PM
BeyondSpring files Form 3 for CFO Na Li showing no beneficial ownership
- PUBT · Jun 29 at 03:31 PM
BeyondSpring amends filing to disclose CEO Min Qiu pay package, including USD 100,000 salary
- TradingView · Jun 4 at 06:33 AM
BeyondSpring appoints Min Qiu as CEO and Na Li as CFO; Lan Huang to remain as Chair
- Earnings Watch · May 13 at 06:02 AM
BeyondSpring | 8-K: FY2026 Q1 Revenue: USD 0
- Zawya · Mar 31 at 11:29 PM
ZAWYA: Beyon holds Annual General Meeting
